CAR T Cell Therapy

Pipeline Programs↗

Active Trials↗

Companies Involved↗

CAR T Cell Therapy is an early-stage landscape with 0 programs across 1 company. The most active players are Hrain Biotechnology Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Hrain Biotechnology Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Recruiting15 · 60%

Unknown status5 · 20%

Active, not recruiting4 · 16%

Completed1 · 4%

Clinical Trials

Trial Activity

25 trials

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT05757219·27 enrolled

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

Recruiting·—·Phase 1/2·NCT07070323·54 enrolled

Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06553898·18 enrolled

Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Recruiting·—·Phase 1·NCT07003568·18 enrolled

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06842589·18 enrolled

Universal CAR-T Cell Therapy for NHL

Recruiting·BBioray Laboratories·N/A·NCT07248163·6 enrolled

BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05846737·20 enrolled

Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration

Recruiting·—·Phase 1·NCT07003555·18 enrolled

Universal CAR-T Cell Therapy for MM

Recruiting·BBioray Laboratories·N/A·NCT07248176·6 enrolled

Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07127289·20 enrolled

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Recruiting·IInstituto de Investigación Biomédica de Salamanca·N/A·NCT06439173·40 enrolled

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Recruiting·—·Phase 1/2·NCT06481735·30 enrolled

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Recruiting·—·Phase 1/2·NCT06014073·30 enrolled

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Recruiting·—·Phase 1/2·NCT07008885·30 enrolled

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

Recruiting·TTianjin Medical University General Hospital·Phase 1/2·NCT06911710·90 enrolled

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)